Nurix Therapeutics, which is developing a protein-degrading approach to fight blood cancers and other diseases, filed for a placeholder $100-million initial public offering (IPO), reported the San Francisco Business Times.
The company also said in its IPO filing with the US Securities and Exchange Commission that it has three protein-degradation programs targeting parts of SARS-CoV-2, the virus that causes COVID-19.
Its lead drugs NX-2127, an oral protein degradation chimeric-targeting molecule aimed at non-Hodgkins lymphoma, and NX-1607, an oral ligase inhibitor, are in preclinical studies.
However, the company hinted in its IPO filing that it soon could file investigational new drug applications with the FDA and then start clinical trials.
Nurix also has invested $3 million in its own spinout company, called DeCART Therapeutics. That company has licensed three Nurix compounds, including cancer-fighting drug-enhanced CAR-T therapies, the news source said.
To read more NewsPoints articles, click here.